Infertility

Signati™ Medical, Inc. Announces Board Member Dr. Jones Joins Urology Austin

Retrieved on: 
Monday, February 12, 2024
Erectile dysfunction, Infertility, Leroy Jones, Male, Urinary incontinence, Urology, Premature ejaculation, Microsurgery, Medicine, MD

Providence, RI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- LeRoy Jones, MD, Board-Certified Urologist and Signati™ Medical, Inc. Board Member, starts a new chapter in his career at Urology Austin.

Key Points: 
  • Providence, RI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- LeRoy Jones, MD, Board-Certified Urologist and Signati™ Medical, Inc. Board Member, starts a new chapter in his career at Urology Austin.
  • Dr. Jones has been on the leading edge of men’s sexual health and prosthetic surgery for decades.
  • As an industry leader in prosthetic surgery, Dr. Jones has performed more than 3,500 penile implants and artificial urinary sphincter procedures.
  • He specializes in erectile dysfunction, erectile growth enhancement, Peyronies Disease, low testosterone, premature ejaculation, urinary incontinence, and male infertility — vasectomies, reversals, and microsurgery.

Brave Healer Productions Announces the Release of The Grief Experience

Retrieved on: 
Monday, February 12, 2024
Breast cancer, Loss, Pain, Connection, Hope, Grief, Trauma center, Death, Knowledge, Caregiver, Infertility, Student, Tourism

BETHESDA, Md., Feb. 12, 2024 /PRNewswire/ -- Brave Healer Productions announces the release of The Grief Experience: Tools for Acceptance, Resilience, and Connection. The new book is helmed by Kelly Daugherty, a social worker and fellow in Thanatology with more than 20 years of clinical experience in grief support and bereavement. The book features a foreword by Dr. Lucy Home, author of Resilient Grieving, and tips and personal experiences from 24 additional authors.

Key Points: 
  • BETHESDA, Md., Feb. 12, 2024 /PRNewswire/ -- Brave Healer Productions announces the release of The Grief Experience: Tools for Acceptance, Resilience, and Connection .
  • The new book is helmed by Kelly Daugherty, a social worker and fellow in Thanatology with more than 20 years of clinical experience in grief support and bereavement.
  • The book features a foreword by Dr. Lucy Home, author of Resilient Grieving, and tips and personal experiences from 24 additional authors.
  • As you read their stories, you'll likely find comfort in connecting with at least one of them, knowing that you're not alone in your journey through grief."

Boston IVF Welcomes Reproductive Endocrinologist Jamil Mroueh, MD to its Rochester Fertility Center Team

Retrieved on: 
Thursday, February 8, 2024
SUNY Downstate Medical Center, American College, American University, Infertility, Greater, REI, MD, Patient, Fertility, IUI, PCOS, ACOG, Acquisition, Education, State university system, Health, IVF, Birth control

 ROCHESTER, Mass., Feb. 8, 2024 /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce that reproductive endocrinologist, Jamil Mroueh, MD has joined its fertility center in Rochester, NY.

Key Points: 
  • Dr. Jamil Mroueh's Arrival Bolsters Access to Prompt Reproductive Care at Boston IVF and its Rochester, NY Fertility Center.
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.
  • Boston IVF's Rochester fertility center is located at 1561 Long Pond Rd Suite 410, Rochester, NY 14626 .
  • "Dr. Mroueh's addition to Boston IVF's Rochester, NY fertility center represents a notable advantage for residents of the Greater Rochester Region and Western New York," stated David Stern, CEO of the Boston IVF fertility network.

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Retrieved on: 
Tuesday, February 6, 2024
Business administration, Lead, Marketing, OvaScience, Spector, Patient, California State University, Employment, IVF, Compensated emancipation, Woman, CCO, Autoimmunity, Diabetes, Infertility, NASA, Johnson & Johnson, Pharmaceutical industry

ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a continuum of commercial stages at both public and private medical device and biopharmaceutical companies.

Key Points: 
  • Mr. Spector has 25 years of experience spanning a continuum of commercial stages at both public and private medical device and biopharmaceutical companies.
  • Mr. Spector has a Bachelor of Science degree in Business Administration and Marketing from California State University in Sacramento, CA.
  • This grant was approved by the Compensation Committee of Femasys’ Board of Directors and made as an inducement material to Mr. Spector entering into employment with Femasys as contemplated by Nasdaq Listing Rule 5635(c)(4).
  • Femasys provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).

Nevada Fertility Center, an Ivy Fertility Clinic, Hires Dr. Gary Levy and Dr. Khurram Rehman

Retrieved on: 
Wednesday, January 31, 2024
Family, Health, Consumer, Women, Other Health, Baby, Maternity, General Health, Infertility, University, MD, Patient, Gynaecology, Obstetrics, University of Michigan, Physician, Associate, OB, Nursing

Ivy Fertility, a collaborative network of globally renowned fertility clinics, is thrilled to welcome Gary Levy, MD and Khurram Rehman, MD to its collaborative team of physicians at Nevada Fertility Center.

Key Points: 
  • Ivy Fertility, a collaborative network of globally renowned fertility clinics, is thrilled to welcome Gary Levy, MD and Khurram Rehman, MD to its collaborative team of physicians at Nevada Fertility Center.
  • Dr. Levy will begin seeing new patients on February 5th, and Dr. Rehman will start later in the month.
  • “We are fortunate to welcome these two accomplished physicians to our Las Vegas clinic,” said Russell Foulk, MD, Medical Director of Nevada Fertility Center.
  • “I am thrilled to be joining their team at Nevada Fertility Center to help patients achieve their goal of becoming parents.”

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Retrieved on: 
Friday, January 26, 2024
APG system, Family, Woman, Infertility, UC, UC Davis Medical Center, University, Food and Drug Administration, University of California, Davis, Safety, FDA, Obstetrics, Medical Center, Clinical trial, Lead, Pharmaceutical industry

UC Davis Medical Center, a top regional and nationally ranked medical center, is the third academic center to participate in the FemBloc pivotal trial since enrollment began last quarter -

Key Points: 
  • UC Davis Medical Center, a top regional and nationally ranked medical center, is the third academic center to participate in the FemBloc pivotal trial since enrollment began last quarter -
    UC Davis Professor of the Obstetrics and Gynecology (OB/GYN) Department and Director of the Complex Family Planning Fellowship, Mitchell Creinin, M.D.
  • The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control (the “FINALE” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc®.
  • The FDA-approved, multi-center trial is designed to address the high unmet need that exists for women seeking permanent birth control, for whom elective surgery currently remains the only option.
  • “I believe that this may be an ideal solution for those seeking an accessible, safe, less financially and emotionally burdensome option to address a basic healthcare need for family planning.”

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Retrieved on: 
Tuesday, January 23, 2024
Woman, University of Utah Hospital, Associate, Infertility, Hormone, History, University, Food and Drug Administration, Risk, Pregnancy, Safety, Obstetrics, FDA

ATLANTA, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced that it has activated enrollment for its pivotal FemBloc trial at another academic site, University of Utah Hospital in Salt Lake City, Utah. The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control (the “FINALE” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc®. The FDA-approved, multi-center trial is designed to help women seeking permanent birth control, for whom elective surgery currently remains the only option.

Key Points: 
  • The FemBloc Intratubal Occlusion for TranscervicAL Permanent Birth Control (the “FINALE” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc®.
  • The FDA-approved, multi-center trial is designed to help women seeking permanent birth control, for whom elective surgery currently remains the only option.
  • Gawron’s consistent involvement demonstrates support for FemBloc and the importance that it may hold in providing optionality to women seeking additional and improved birth control options."
  • An in-office option like FemBloc has the opportunity to change how we deliver care to women when they no longer wish to be at risk of pregnancy but no longer want exposure to hormones or implants or surgery.”

Los Angeles Vasectomy and Vasectomy Reversal Specialist, Dr. Justin Houman, is Appointed Assistant Professor at Cedars-Sinai Medical Center

Retrieved on: 
Tuesday, January 23, 2024
Student, LOS, Patient, American Urological Association, Infertility, General surgery, Peyronie's disease, Health, Urology, Multimedia, Knowledge, Male, Reproductive medicine, Men's Health, University, Quality of life, Vasectomy, Incontinence, Suite, Erectile dysfunction, Cedars-Sinai Medical Center, International Society, Education, Testosterone, Physician, Birth control

LOS ANGELES, Jan. 23, 2024 /PRNewswire-PRWeb/ -- As an esteemed assistant professor in urology at Cedars-Sinai Medical Center, Dr. Justin Houman will continue enhancing the quality of life for men by improving their sexual, reproductive and hormonal health. Dr. Houman provides his patients with the latest and most effective treatments available, with extensive expertise in vasectomy, vasectomy reversal, infertility, testosterone, Peyronie's disease, erectile dysfunction and urology. Also, as a top minimally invasive microscopic surgeon, Dr. Houman delivers skill and expertise in microsurgical varicocelectomies, vasectomy reversals, sperm retrievals, penile implants and male incontinence. His vast knowledge and experience in urology have earned him recognition as a leading authority in men's health. Dr. Houman's appointment at Cedars-Sinai Medical Center is a testament to his exceptional skills, dedication and unwavering commitment to patient care. As an assistant professor, Dr. Houman will continue to contribute to the advancement of urological research and education for his patients and students.

Key Points: 
  • Board-certified and fellowship-trained urologist, Dr. Justin Houman, is a top men's health specialist and leading urological surgeon in the Los Angeles area.
  • LOS ANGELES, Jan. 23, 2024 /PRNewswire-PRWeb/ -- As an esteemed assistant professor in urology at Cedars-Sinai Medical Center, Dr. Justin Houman will continue enhancing the quality of life for men by improving their sexual, reproductive and hormonal health.
  • Dr. Houman provides his patients with the latest and most effective treatments available, with extensive expertise in vasectomy, vasectomy reversal , infertility, testosterone, Peyronie's disease, erectile dysfunction and urology.
  • Dr. Houman's appointment at Cedars-Sinai Medical Center is a testament to his exceptional skills, dedication and unwavering commitment to patient care.

Accolade Welcomes Kindbody to Trusted Partner Ecosystem

Retrieved on: 
Tuesday, January 23, 2024
Fertility, Infertility, Health, IVF, Partnership, Female, Male, Menopause, Workplace, Genetic testing, Trusted Partner, Education, ACCD, Birth control

SEATTLE, Jan. 23, 2024 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) today announced that Kindbody, a technology-driven fertility clinic network and family-building benefits provider for employers, will join the company's Trusted Partner Ecosystem to offer Accolade customers comprehensive, clinically guided support and care throughout a member's fertility and family-building journey, all backed by a new cost savings performance guarantee.

Key Points: 
  • Kindbody addresses these issues by providing affordable fertility care and delivering a seamless, integrated experience with best-in-class outcomes.
  • Kindbody delivers this model through a combination of owned and operated signature clinics and hundreds of partner clinics nationwide.
  • Joint customers of Accolade and Kindbody will benefit from integrations designed to promote awareness of Kindbody's services, at no incremental cost to customers.
  • Launched in 2019, Accolade's Trusted Partner Ecosystem is the first in the industry to bring together multiple benefits solutions across valued categories, making them available to employers through a single front door.

Vistia Health selects Progyny as its preferred fertility and family building benefits provider

Retrieved on: 
Wednesday, January 17, 2024
Family, Partnership, World Health Organization, Pregnancy, Fertility, Infertility, Prevalence, Birth control

PHILADELPHIA, Jan. 17, 2024 /PRNewswire/ -- Vistia Health, a healthcare navigator supporting whole-person health journeys, today announced that it has selected Progyny, Inc. to be the preferred fertility and family building benefits provider for Vistia Health clients. Progyny, Inc (Nasdaq: PGNY) is a leading benefits management company specializing in fertility and family building benefits solutions.

Key Points: 
  • PHILADELPHIA, Jan. 17, 2024 /PRNewswire/ -- Vistia Health , a healthcare navigator supporting whole-person health journeys, today announced that it has selected Progyny, Inc. to be the preferred fertility and family building benefits provider for Vistia Health clients.
  • Progyny, Inc (Nasdaq: PGNY) is a leading benefits management company specializing in fertility and family building benefits solutions.
  • "We've seen strong demand for family building benefits as clients begin to further recognize the diverse needs of individuals embarking on their family building journeys," said Dave Stefanski, director, Vistia Health.
  • We're excited to partner with Vistia Health as its preferred fertility and family building solution," said Michael Sturmer, Progyny president.